I understand your point and it's well taken. But, we do still see a lot of Phase 2 trial results that do attain statistical significance and, all things being equal, I'd much rather back a drug that has attained statistical significance in a Phase 2 than one that has not.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.